Brought to you by 
Celgene and Agios enter new deal focused on metabolic immuno-oncology
27 Oct 2021
Executive Summary
Building on a successful relationship that began in 2010, Celgene Corp. and Agios Pharmaceuticals Inc. entered into a new collaboration, this time focused on metabolic immuno-oncology, which involves altering the metabolic state of immune cells to enhance immune response to cancer.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Immuno-Oncology
Deal Status
- Final
Deal Type
-
Alliance
- Co-Promotion
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Celgene and Agios enter new deal focused on metabolic immuno-oncology
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice